• Subscribe
  • About us
  • Advertise with us

NeuroSens

Menu

Skip to content
  • Home
  • Neurology
  • Psychiatry

Topic: BIOMARKERS IN MS

NfL – a guide to use in MS practice

May 31, 2023  

Emerging role of CHI3L1 as MS biomarker

May 2, 2023  

AAN 2023 HIGHLIGHTS – WEDNESDAY, APRIL 26

April 26, 2023  

AAN 2023 HIGHLIGHTS – TUESDAY, APRIL 25

April 25, 2023  

AAN 2023 HIGHLIGHTS – MONDAY, APRIL 24

April 24, 2023  

sNfL a biomarker of future disease activity: APLIOS

April 12, 2023  

Putting biomarkers into practice

March 8, 2023  

ECTRIMS 2022 SLIDE DECK

November 10, 2022  

ECTRIMS 2022 HIGHLIGHTS – FRIDAY, OCTOBER 28 EDITION

October 28, 2022  

Three biomarkers of DMT adverse effects proposed

August 25, 2022  
Previous
3
4
5
6
7
Next

Browse by Topic

  • MS (439)
  • CLINICAL CASES (21)
  • AAN 2026 (3)
  • ACTRIMS Forum 2026 (4)
  • EPILEPSY (38)
  • AES 2025 (1)
  • BIOMARKERS IN MS (61)
  • ECTRIMS 2025 (7)
  • Library (18)
  • EAN 2025 (2)
  • AAN 2025 (5)
  • ACTRIMS 2025 (6)
  • AES 2024 (1)
  • ECTRIMS 2024 (6)
  • EAN 2024 (3)
  • AD (85)
  • AAN 2024 (5)
  • ACTRIMS Forum 2024 (2)
  • PD (77)
  • COVID-19 (58)
  • MIGRAINE (25)
  • DEPRESSION (36)
  • STROKE (22)
  • SCHIZOPHRENIA (25)
  • DEMENTIA (10)
  • SLEEP (2)
  • PAIN (3)
  • BPD (4)
  • ALS (1)

Popular Posts

  • Beyond remission: redefining the goal of schizophrenia management posted on August 4, 2015
  • Proton pump inhibitors linked to neurological conditions posted on November 29, 2019
  • Emerging Treatment Goals in Schizophrenia – Toward Functional Recovery posted on November 3, 2017
Copyright 2026 Lind Publishing Inc All rights reserved. Developed by Integration New Media, INC. (INM)
Contact Us Terms and Conditions